Effectiveness of a systematic vaccination program in patients with autoimmune inflammatory disease treated with anti-TNF alpha drugs.
Sergio Fernandez-Martinez, Xavier Cortes, Joaquín Borrás-Blasco...
https://pubmed.ncbi.nlm.nih.gov/27537179/Actively Recruiting
Led by University of Sao Paulo General Hospital · Updated on 2026-07-20
477
Participants Needed
2
Research Sites
52 weeks
Total Duration
This research aims to evaluate the safety and immune response of the live attenuated tetravalent Butantan-Dengue vaccine Butantan-DV in people aged 12 to 59 years with autoimmune rheumatic diseases ARDs who are clinically stable and under low-grade or no immunosuppression, compared to healthy volunteers matched by age and sex. The study addresses important questions about whether the vaccine triggers adequate antibody responses, the frequency and intensity of common side effects, and how physical activity and nutrition might affect vaccine response in ARD patients. Participants will receive a single 0.5 mL dose of the Butantan-DV vaccine by subcutaneous injection on Day 1. Follow-up visits for safety and laboratory tests occur on Days 7, 14, and 42, with long-term monitoring extending to Day 400 to assess antibody persistence and late safety signals. A subgroup will undergo additional blood sampling to evaluate viremia up to Day 68 if detected, and about 20% of participants will have cellular immune response testing at baseline, Day 42, and Day 400. Participants will provide blood samples before vaccination, at Day 42, and one year after to assess immune response. They will report symptoms and adverse events for 42 days using a diary, wear a device for 14 days to monitor physical activity, and complete dietary recalls to evaluate nutrition. Disease activity and safety will be closely monitored throughout, with assessments to distinguish vaccine effects from disease flares. The study duration for participants extends up to one year after vaccination.
CONDITIONS
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
C
Clovis A Silva, Full Professor
E
Eloisa SDO Bonfa, Full Professor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Sao Paulo General Hospital
Lead Sponsor
Butantan Institute
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 42 days
Participants receive a single 0.5 mL dose of the Butantan-Dengue vaccine subcutaneously on Day 1. Follow-up visits occur on Days 7, 14, and 42 for safety monitoring and laboratory tests. Participants report symptoms and adverse events using a diary for 42 days.
4 visits including vaccination and follow-ups
Duration - Up to 400 days
Participants are monitored up to one year after vaccination to assess antibody persistence, cellular immune responses, disease activity flares, and serious adverse events.
Periodic blood sample visits including Day 400
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sergio Fernandez-Martinez, Xavier Cortes, Joaquín Borrás-Blasco...
https://pubmed.ncbi.nlm.nih.gov/27537179/Shibadas Biswal, Humberto Reynales, Xavier Saez-Llorens...
https://pubmed.ncbi.nlm.nih.gov/31693803/Esper G Kallás, Monica A T Cintra, José A Moreira...
https://pubmed.ncbi.nlm.nih.gov/38294972/Stephen J Thomas, In-Kyu Yoon
https://pubmed.ncbi.nlm.nih.gov/31589551/University of Sao Paulo General Hospital
Lead Sponsor
Butantan Institute
Collaborating Sponsor